Beta-1,3-Glucan Modulation of Immune Function and Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hyperlipidemia, metabolic syndrome, inflammatory bowel disease, colitis, Crohn's disease, and colon cancer often have side effects and are not effective enough, and there is a need for more natural methods to modulate immune function and prevent intestinal inflammation.
Innovation Solution
Administering beta-1,3-glucan derived from Euglena grown using fermentation, either as a purified form or as part of Euglena biomass, to modulate immune function and treat the mentioned conditions, which can be combined with other supplements and administered orally or in combination with conventional medications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional medicines are administered to treat hyperlipidemia, metabolic syndrome, inflammatory bowel disease, colitis, Crohn's disease, and colon cancer, then disease treatment is achieved, but undesirable side effects occur
Solution Approach 1:
The patent employs beta-1,3-glucan, a natural polysaccharide derived from fungi or plants, as a temporary and biodegradable therapeutic agent. This natural substance provides disease treatment effects while avoiding the long-term accumulation and severe side effects associated with conventional synthetic medicines, aligning with the principle of using safe, disposable-like natural compounds that decompose harmlessly in the body.
Solution Approach 2:
Beta-1,3-glucan acts as an intermediary substance that modulates the immune system and reduces inflammation without directly attacking the disease target. It serves as a bridge between the patient's immune system and the disease process, providing therapeutic effects through immune modulation rather than direct pharmacological action, thereby reducing harmful side effects.
2Reliability
If conventional medicines are administered to treat intestinal inflammation, then disease treatment is achieved, but the treatment is not effective enough
Solution Approach 1:
The patent utilizes beta-1,3-glucan with specific molecular weight ranges (10,000 to 1,000,000 Da) and specific structural characteristics (beta-1,3-glycosidic bonds) to optimize its therapeutic efficacy. By controlling these parameters, the glucan achieves enhanced ability to bind to immune cells and modulate inflammation, providing more effective treatment results compared to conventional medicines.
Solution Approach 2:
The patent employs beta-1,3-glucan as a composite therapeutic agent that combines multiple biological activities including immune modulation, anti-inflammation, and antioxidant effects. This composite natural substance provides synergistic treatment effects that are more effective than single-mechanism conventional medicines.
3Reliability
If beta-1,3-glucan is administered to modulate immune function, then immune enhancement is achieved, but the mechanism is complex
Solution Approach 1:
The patent segments the complex immune modulation mechanism into distinct functional steps: beta-1,3-glucan binds to complement receptor 3 or dectin-1 on macrophages, initiates phagocytosis, and triggers cytokine production. This segmentation of the mechanism into discrete, identifiable steps simplifies understanding while maintaining the complexity of the biological process.
Solution Approach 2:
Beta-1,3-glucan serves as an intermediary that simplifies the complex immune response by providing a consistent binding interface (complement receptor 3 or dectin-1) on immune cells. This intermediary substance translates complex immune signaling into a standardized response pathway, making the mechanism more manageable and predictable.
4Object-affected harmful factors
If natural methods are used to prevent intestinal inflammation, then side effects are reduced, but treatment effectiveness is insufficient
Solution Approach 1:
The patent optimizes the parameters of beta-1,3-glucan including molecular weight (10,000 to 1,000,000 Da), purity (greater than 90%), and concentration (0.1 mg to 100 mg per kg body weight) to achieve both natural safety and effective treatment. These parameter optimizations ensure that the natural substance provides sufficient therapeutic efficacy while maintaining its side-effect-free profile.
Solution Approach 2:
The patent employs purified beta-1,3-glucan as a high-quality natural material that combines the safety of natural substances with the effectiveness of potent therapeutic agents. The purification process (achieving greater than 90% purity) removes harmful contaminants while preserving the active therapeutic components, creating a composite material that is both safe and effective.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The administration of beta-1,3-glucan from Euglena effectively reduces cholesterol and triglyceride levels, enhances immune function, and increases anti-inflammatory cytokine production, providing a natural and side-effect-reduced treatment option for the mentioned conditions.
Implementation Method 1
beta glucan derived from yeast can impact immune function by binding complement receptor 3 or dectin-1 on macrophages
Implementation Method 2
beta glucan interacts with cell surface receptors to initiate a cascade of events including phagocytosis and the production of certain cytokines
Implementation Method 3
beta-1,3-glucan from Euglena grown using fermentation
Data Source
AI summary
The present application relates to beta-1,3-glucan and uses thereof to modulate immunity in the human body. Also provided are methods for treatment and/or prevention of high cholesterol, diabetes, and allergies. Also provided are methods for treatment and/or prevention of intestinal inflammation.